GLP-1 and Joint Health

The obesity-joint pain connection

Osteoarthritis (OA) is the most common joint condition in the UK, affecting approximately 8.75 million people. Obesity is the single strongest modifiable risk factor for developing knee osteoarthritis and a significant contributor to hip and hand OA. The relationship is driven by two complementary mechanisms: mechanical overloading and systemic inflammation.

Mechanical load

Weight-bearing joints — particularly the knees, hips, ankles and lower spine — absorb forces many times greater than body weight during everyday activities. During walking, the knee experiences a load of approximately 3–4 times body weight with each step. During stair climbing, this rises to 4–5 times. During running, 6–8 times.

This mechanical amplification means that even modest weight gain has a disproportionate impact on joint stress. Conversely, every kilogram lost reduces the load on the knee by approximately four kilograms per step. A patient who loses 15 kg on Wegovy or Mounjaro reduces their knee load by approximately 60 kg with every step — a transformation that accumulates across the thousands of steps taken daily.

Inflammatory pathway

Obesity is a state of chronic low-grade inflammation. Adipose tissue (body fat) is metabolically active and secretes pro-inflammatory cytokines including IL-6, TNF-alpha and adipokines such as leptin and resistin. These inflammatory mediators circulate throughout the body and directly accelerate cartilage degradation, even in non-weight-bearing joints.

This explains why obesity increases the risk of hand osteoarthritis, which carries no mechanical load advantage. It also explains why GLP-1 receptor agonists, which reduce systemic inflammation independently of weight loss, may have additional joint-protective effects.

Evidence from GLP-1 clinical trials

STEP trials: joint pain outcomes

The STEP clinical trial programme for semaglutide (Wegovy) included patient-reported outcome measures for physical function and joint pain. Patients who achieved 15% or greater weight loss reported clinically meaningful improvements in:

• Knee and hip pain scores (visual analogue scale)
• Physical function (ability to walk, climb stairs, perform daily activities)
• Mobility and flexibility
• Health-related quality of life (SF-36 physical component scores)

SURMOUNT trials: tirzepatide outcomes

The SURMOUNT-1 trial of tirzepatide (Mounjaro), which achieved even greater weight loss (up to 22.5%), reported significant improvements in physical functioning. Patients at the 15 mg dose showed the greatest gains, consistent with a dose-response relationship mediated by weight loss.

Dedicated osteoarthritis studies

Several smaller studies have specifically investigated GLP-1 RA effects on osteoarthritis outcomes:

• A 2024 Danish observational study found that patients with knee OA who took semaglutide for 12 months reported a 40% reduction in WOMAC pain scores, alongside improvements in stiffness and physical function.
• Pre-clinical research (animal models) suggests that GLP-1 receptor activation may directly protect cartilage by reducing chondrocyte apoptosis and inhibiting matrix metalloproteinases (MMPs) that break down cartilage.
• The LOSEIT-OA trial (semaglutide in knee osteoarthritis) is currently recruiting in the UK and expected to report in 2027, providing the first large-scale randomised evidence specifically for this indication.

Benefits for specific joint conditions

Knee osteoarthritis

The knee is the joint most affected by obesity. Weight loss of 10% or more consistently produces clinically significant improvement in knee OA symptoms. With GLP-1 RAs achieving 15–22% weight loss, the knee benefits are substantial. Many patients report being able to walk further, climb stairs more easily and reduce or discontinue anti-inflammatory painkillers.

Hip osteoarthritis

The hip joint also bears significant body weight load, though the biomechanical amplification is less extreme than the knee (approximately 2–3 times body weight during walking). Weight loss improves hip OA symptoms, and reduced systemic inflammation provides additional benefit.

Lower back pain

Obesity is a major risk factor for chronic lower back pain, both through mechanical loading of the lumbar spine and through systemic inflammation affecting intervertebral discs. Significant weight loss frequently improves back pain and may reduce the need for spinal interventions.

Gout

Gout is an inflammatory arthritis caused by uric acid crystal deposition. Obesity is a strong risk factor because adipose tissue increases uric acid production and reduces renal clearance. Weight loss on GLP-1 RAs reduces serum uric acid levels, decreasing gout flare frequency. Some patients experience a temporary increase in gout attacks during rapid weight loss due to uric acid mobilisation — discuss prophylaxis with your GP if you have a history of gout.

Inflammatory arthritis

For patients with rheumatoid arthritis or psoriatic arthritis alongside obesity, weight loss improves disease activity scores and treatment response. The anti-inflammatory effects of GLP-1 RAs may provide additional benefit, though this is not yet proven in clinical trials for inflammatory arthritis.

GLP-1 medications and joint surgery

For patients considering joint replacement surgery (knee or hip arthroplasty), weight loss before the operation is strongly recommended by orthopaedic guidelines.

Pre-surgical weight optimisation

Many NHS orthopaedic departments have BMI thresholds for elective joint replacement, commonly requiring a BMI below 35–40 kg/m². Patients above these thresholds are often referred for weight management before surgery. GLP-1 medications can help patients reach these targets.

Avoiding surgery altogether

For some patients, the combination of significant weight loss and structured exercise may delay or eliminate the need for joint replacement. A 2023 meta-analysis found that patients who lost more than 10% body weight and engaged in regular strengthening exercises had a 30–40% lower rate of proceeding to knee replacement over 5 years compared to those who did not lose weight.

Exercise guidance for joint health on GLP-1

Combining GLP-1 medication with appropriate exercise produces the best joint health outcomes. Our guide on exercise whilst on GLP-1 medication covers general principles, but here are joint-specific recommendations:

Recommended exercises

• Swimming and water aerobics: Buoyancy reduces joint load by up to 90% whilst providing resistance for muscle strengthening. Ideal for patients with moderate to severe OA.
• Cycling (stationary or outdoor): Low-impact, excellent for knee range of motion and quadriceps strengthening.
• Walking: Start with flat terrain and short distances, gradually increasing. Use supportive footwear.
• Resistance training: Critical for strengthening muscles that support joints, particularly the quadriceps (for knee OA) and gluteal muscles (for hip OA). This also helps prevent muscle loss associated with weight loss.
• Tai chi and yoga: Improve balance, flexibility and joint proprioception with minimal impact. NICE CG177 specifically recommends tai chi for knee OA.

Exercises to approach with caution

• Running on hard surfaces — high impact on weight-bearing joints
• Deep squats and lunges — may overload arthritic knees
• High-impact aerobics — jumping movements stress joints
• Heavy overhead lifting — can compress the spine

Nutritional support for joints

A well-planned diet on GLP-1 medication should include nutrients that support joint health:

• Omega-3 fatty acids: Oily fish (salmon, mackerel, sardines) twice weekly, or supplementation. Anti-inflammatory effects benefit joints.
• Vitamin D: Essential for bone health. Many UK adults are deficient, particularly in winter. PHE recommends supplementation (10 mcg/day) for all adults October to March.
• Calcium: Adequate intake (700 mg/day for adults) supports bone density alongside weight loss. Dairy products, fortified plant milks, leafy greens.
• Protein: 1.2–1.6 g/kg body weight daily to preserve muscle mass that supports joints.
• Collagen: Some evidence suggests collagen peptide supplementation (10 g/day) may support cartilage health, though evidence is limited.

Frequently asked questions

Can GLP-1 medications help with joint pain?

Yes, primarily through weight loss. Every kilogram lost reduces knee joint load by approximately four kilograms. Additionally, GLP-1 RAs have anti-inflammatory effects that may directly benefit joint health. Patients losing 15% or more of body weight typically report clinically meaningful pain improvement.

Does losing weight on Ozempic help osteoarthritis?

Yes. Weight loss is a NICE-recommended core treatment for osteoarthritis. The magnitude of weight loss achieved with GLP-1 RAs (15–22%) significantly exceeds the 5–10% that produces meaningful symptom improvement in clinical studies.

Can GLP-1 medication help me avoid joint replacement surgery?

For some patients, significant weight loss combined with exercise may delay or eliminate the need for surgery. It can also help patients reach the BMI thresholds that many NHS orthopaedic departments require before offering elective joint replacement.

Is it safe to exercise with joint pain whilst on GLP-1 medication?

Yes, and it is recommended. Low-impact activities (swimming, cycling, walking, tai chi) strengthen muscles around joints and enhance weight loss. A physiotherapist can design a safe programme tailored to your condition.

Will my joint pain come back if I stop GLP-1 medication?

If you regain weight after stopping GLP-1 medication, joint symptoms are likely to return. This is why long-term weight management and sustained exercise habits are essential for maintaining joint health benefits.

Sources

• NICE — Osteoarthritis: care and management (CG177)
• NICE — Obesity: identification, assessment and management (CG189)
• MHRA — Summary of Product Characteristics: Wegovy, Ozempic, Mounjaro
• BNF — Semaglutide, Tirzepatide monographs (bnf.nice.org.uk)
• Messier SP et al. Effects of intensive diet and exercise on knee joint loads. N Engl J Med 2013; 369:1195–1205
• Bliddal H et al. Osteoarthritis, obesity and weight loss. Obes Rev 2014; 15:578–586
• Wilding JPH et al. STEP 1. N Engl J Med 2021; 384:989–1002
• Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022; 387:205–216
• Versus Arthritis — Osteoarthritis information (versusarthritis.org)
• NHS — Osteoarthritis (nhs.uk/conditions/osteoarthritis)
• PHE — Vitamin D supplementation guidance